AKANTIOR (polihexanide) is the first and only medicinal product for the treatment of acanthamoeba keratitis – a rare, severe eye infection that often results in blindness and eye loss The marketing ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved polihexanide (Akantior) to treat acanthamoeba keratitis. Acanthamoeba keratitis is an infection of the cornea, the clear ...

As with any medicine, the MHRA will keep the safety and effectiveness of polihexanide under close review. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved polihexanide ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) today revealed it has approved Akantior (polihexanide) to treat acanthamoeba keratitis (AK). The approval was granted to Italian ...

CATANIA, Italy, May 19, 2025 /PRNewswire/ -- SIFI, a leading international ophthalmic company, today announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted the ...

CATANIA, Italy, March 18, 2025 /PRNewswire/ -- SIFI, a leading international pharmaceutical company specializing in ophthalmology, is pleased to announce a scientific collaboration with the University ...

CATANIA, Italy, Sept. 30, 2024 /PRNewswire/ -- SIFI, a leading international ophthalmic company, announced that is has received a Notice of Allowance from the European Patent Office ("EPO") for ...